New research reveals that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a leading medical journal points out that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing such treatments must be aware of the potential of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass in about 18 months.
Comparing Therapies
The study, which examined 37 of studies involving over 9,000 of participants, compared the results of the injectable medications with older methods.
The team emphasize that people who shed pounds through lifestyle changes alone usually see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Doctors propose the mode of action of the jabs explains the accelerated weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal might result in the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to appetite is uncontrolled, making overeating much more probable."
A Chronic Condition?
Health authorities suggest the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, due to the likelihood of relapse, the therapy might need to be ongoing.
This opinion is echoed by drug manufacturers, who note that the results "underscore the persistent nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
People who have stopped the jabs report a intense resurgence of hunger.
"I experienced a switch that goes on and you become extremely hungry," described one woman.
This challenge is compounded if patients have not established sustainable dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while the jabs are effective tools for weight loss, they are not a standalone fix and lasting health benefits relies on ongoing behavioural support.
